Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
242
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+3.95M
-
Total reported value, excl. options
-
$1.92B
-
Value change
-
+$255M
-
Put/Call ratio
-
1.46
-
Number of buys
-
136
-
Number of sells
-
-65
-
Price
-
$60.90
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2019
287 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2019.
CRISPR Therapeutics AG - Common Stock (CRSP) has 242 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 86M outstanding shares and own 36.66% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (4.21M shares), Nikko Asset Management Americas, Inc. (3.05M shares), ARK Investment Management LLC (2.96M shares), NEA Management Company, LLC (2.09M shares), FEDERATED HERMES, INC. (1.26M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.11M shares), WADDELL & REED FINANCIAL INC (1.03M shares), Cormorant Asset Management, LP (1M shares), FMR LLC (952K shares), and ORBIMED ADVISORS LLC (766K shares).
This table shows the top 242 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.